Posted by Michael Wonder on 30 Apr 2020
Health economic assessment of Keytruda in head and neck cancer
29 April 2020 - TLV has developed a health economic knowledge base for the regions of the drug Keytruda (pembrolizumab).
The documentation applies to Keytruda as a single treatment or in combination with chemotherapy for the treatment of adult patients with metastatic or recurrent cancer of the head and neck whose tumours express PD-L1.
With the assumptions that TLV considers most relevant, the health economic analysis leads to a cost per year of quality-adjusted life-years of SEK 490,000 for Keytruda as a single treatment and SEK 560,000 for Keytruda in combination with platinum-based chemotherapy and 5-fluorouracil.
